These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 1605901)

  • 1. Life-threatening hyperkalaemia in an elderly patient receiving captopril, furosemide (frusemide) and potassium supplements.
    Chan TY; Critchley JA
    Drug Saf; 1992; 7(2):159-61. PubMed ID: 1605901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined therapy with captopril and potassium supplementation. A potential for hyperkalemia.
    Burnakis TG; Mioduch HJ
    Arch Intern Med; 1984 Dec; 144(12):2371-2. PubMed ID: 6391404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of combined therapy with captopril, furosemide, and a sodium-restricted diet on serum electrolyte concentrations and renal function in normal dogs and dogs with congestive heart failure.
    Roudebush P; Allen TA; Kuehn NF; Magerkurth JH; Bowers TL
    J Vet Intern Med; 1994; 8(5):337-42. PubMed ID: 7837109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversible renal failure after combined treatment with enalapril and frusemide in a patient with congestive heart failure.
    Funck-Brentano C; Chatellier G; Alexandre JM
    Br Heart J; 1986 Jun; 55(6):596-8. PubMed ID: 3013264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Life-threatening hyperkalemia associated with captopril administration.
    Doman K; Perlmutter JA; Muhammedi M; Puschett JB
    South Med J; 1993 Nov; 86(11):1269-72. PubMed ID: 8235783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of captopril therapy on lymphocyte potassium and magnesium concentrations in patients with congestive heart failure.
    O'Keeffe S; Grimes H; Finn J; McMurrough P; Daly K
    Cardiology; 1992; 80(2):100-5. PubMed ID: 1611628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Captopril: reversible renal failure with severe hyperkalaemia.
    Grossman A; Eckland D; Price P; Edwards CR
    Lancet; 1980 Mar; 1(8170):712. PubMed ID: 6103125
    [No Abstract]   [Full Text] [Related]  

  • 8. [Dangerous hyperkalemia as sequelae of new treatment strategies of heart failure].
    Fuster D; Frey FJ; Ferrari P
    Praxis (Bern 1994); 2000 Dec; 89(49):2073-6. PubMed ID: 11190849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reversible renal failure after combined treatment with enalapril and frusemide in a patient with congestive heart failure.
    Stewart JT; Lovett D; Joy M
    Br Heart J; 1986 Nov; 56(5):489-90. PubMed ID: 3024687
    [No Abstract]   [Full Text] [Related]  

  • 10. Serum concentration of potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate, losartan potassium or candesartan cilexetil.
    Saito M; Takada M; Hirooka K; Isobe F; Yasumura Y
    J Clin Pharm Ther; 2005 Dec; 30(6):603-10. PubMed ID: 16336294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Captopril induced reversible acute renal failure in a premature neonate with double outlet right ventricle and congestive heart failure.
    Tan LH; Du LZ; Carr MR; Kuzin JK; Moffett BS; Chang AC
    World J Pediatr; 2011 Feb; 7(1):89-91. PubMed ID: 21191783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors associated with a high velocity of the development of hyperkalaemia in hospitalised patients.
    Indermitte J; Burkolter S; Drewe J; Krähenbühl S; Hersberger KE
    Drug Saf; 2007; 30(1):71-80. PubMed ID: 17194172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized trial of saline hydration to prevent contrast-induced nephropathy in patients on regular captopril or furosemide therapy undergoing percutaneous coronary intervention.
    Shemirani H; Pourrmoghaddas M
    Saudi J Kidney Dis Transpl; 2012 Mar; 23(2):280-5. PubMed ID: 22382219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adverse effects of converting-enzyme inhibition in patients with severe congestive heart failure: pathophysiology and management.
    Packer M; Kessler PD; Gottlieb SS
    Postgrad Med J; 1986; 62 Suppl 1():179-82. PubMed ID: 3022272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug attributed alterations in potassium handling in congestive cardiac failure.
    Lawson DH; O'Connor PC; Jick H
    Eur J Clin Pharmacol; 1982; 23(1):21-5. PubMed ID: 7128669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reversible renal failure due to captopril in a patient with transplant artery stenosis. Case report.
    Mason JC; Hilton PJ
    Hypertension; 1983; 5(4):623-7. PubMed ID: 6345368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Provocation of hyper- and hypokalemic sudden death during treatment with and withdrawal of converting-enzyme inhibition in severe chronic congestive heart failure.
    Packer M; Lee WH
    Am J Cardiol; 1986 Feb; 57(4):347-8. PubMed ID: 3004185
    [No Abstract]   [Full Text] [Related]  

  • 19. Arrhythmias during concurrent therapy with captopril and frusemide.
    Daniels AR
    N Z Med J; 1987 Nov; 100(835):695. PubMed ID: 3330600
    [No Abstract]   [Full Text] [Related]  

  • 20. Acute tubular necrosis due to captopril.
    Al Shohaib S; Raweily E
    Am J Nephrol; 2000; 20(2):149-52. PubMed ID: 10773617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.